Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Latuda

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

- PMLiVE

US filing aims to elevate Brintellix above its competition

Drug looking for an edge in the highly competitive major depressive disorder market

- PMLiVE

New iPad app helps schizophrenia patients

Research shows the app ‘Wizard’ could aid memory and independence

RRD International hires Ulrich Thienel as CDMO

Company expands leadership team with former Takeda VP

- PMLiVE

Takeda files ‘oral Velcade’ for myeloma in US

Follow up could be the first pill approved for this rare cancer

- PMLiVE

Adam Zaeske appointed as new MD of Takeda UK

Promoted after 11 years with the company

Allergan logo

More waiting for Allergan and Gedeon Richter’s antipsychotic

FDA announced it will take another three months to review cariprazine for schizophrenia

- PMLiVE

FDA approves J&J’s schizophrenia drug Invega Trinza

New version of Invega is the first treatment for the condition to require only four doses a year

UK flag

London life science growth boosted by Takeda

Japanese firm adds to recent surge in pharma spending in the capital

- PMLiVE

Takeda strengthens leadership team with business unit director

Craig Adkins takes up the position after being at the firm for ten years

- PMLiVE

Takeda to pay $2.4bn to settle Actos cancer suits

Will be one of the largest drug safety settlements in US history

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links